Giant cell arteritis (GCA) presents differently in early stages of the disease, early diagnosis is vital in reducing more severe symptoms such as sight loss. In this interview with Prof. Bhaskar Dasgupta (Southend University Hospital NHS Foundation Trust, Southend-on-Sea, UK) we discuss the difficulties in diagnosing GCA and why early diagnosis is so crucial.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Probability-based Diagnostic Algorithm in Suspected Giant Cell Arteritis: A Prospective, Multicentre Validity Data from HAS GCA Study‘ (Abstract number: 1620) was presented at the ACR Convergence, November 10–14, 2022.
- What are the challenges in the diagnosis of giant cell arteritis (GCA)? (1:51)
Disclosures: Bhaskar Dasgupta discloses consulting for Sanofi; receiving grant/ research support from Sanofi; and receiving honoraria from Sanofi.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of the ACR Convergence 2022.
Share this Video
Related Videos In Vasculitis
Molecular phenotyping of giant cell arteritis patients based on the serum protein signature: Lisa Christ, EULAR 2023
There is a lack of biomarkers to profile phenotypes in giant cell arteritis (GCA) and predict potential complications. Serum protein profiling may identify molecular-based phenotypes and facilitate personalized medicine approaches. touchIMMUNOLOGY were delighted to speak with Dr Lisa Christ (Universitätsspital Bern Bern, Switzerland) about her study which investigated the serum protein signature of clinically defined GCA […]
Molecular Phenotyping of Giant Cell Arteritis: Lisa Christ, EULAR 2023
Giant cell arteritis (GCA) is a primary systemic vasculitis characterised by systemic inflammation and vascular insufficiency of large and medium blood vessels which may lead to end-organ damage in patients age 50 and older. touchIMMUNOLOGY were delighted to speak with Dr Lisa Christ (Universitätsspital Bern Bern, Switzerland) about the unmet needs in the pathogenesis of […]
Naomi J Patel, ACR 2022: Impact of tocilizumab on HbA1C during giant cell arteritis treatment
GiACTA was a randomized, double-blind, placebo-controlled study that investigated the safety and efficacy of tocilizumab, an IL-6 receptor antagonist, in patients with giant cell arteritis. touchIMMUNOLOGY were delighted to speak with Dr. Naomi J Patel (Massachusetts General Hospital, Boston, MA, USA) to discuss the aims, design and findings from her post-hoc analysis of the GiACTA […]